| scholarly article | Q13442814 |
| P2093 | author name string | Hui Liu | |
| Zhen Yang | |||
| Cheng-Yong Qin | |||
| Guo-Qing Han | |||
| Hong-Wei Xu | |||
| Mei Meng | |||
| P2860 | cites work | The retinoblastoma protein and cell cycle control | Q27860722 |
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| p21 is a universal inhibitor of cyclin kinases | Q28257305 | ||
| p21 is necessary for the p53-mediated G1 arrest in human cancer cells | Q28291118 | ||
| Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis | Q28585138 | ||
| Cyclins and cyclin-dependent kinases: a biochemical view | Q28611449 | ||
| Principles of CDK regulation | Q29547820 | ||
| Inhibitors of mammalian G1 cyclin-dependent kinases | Q29547907 | ||
| Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells | Q31858506 | ||
| An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer | Q33180857 | ||
| Cell cycle regulators and their abnormalities in breast cancer | Q33588357 | ||
| Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle | Q34296821 | ||
| Control of the cell cycle | Q35787036 | ||
| The retinoblastoma susceptibility gene product represses transcription when directly bound to the promoter | Q38296590 | ||
| Simple and complex cell cycles | Q38368830 | ||
| Primary liver cancers | Q40424480 | ||
| Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells | Q40538652 | ||
| Molecular thanatopsis: a discourse on the BCL2 family and cell death. | Q41025122 | ||
| Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. | Q41038298 | ||
| Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis | Q41094002 | ||
| New members of the Bcl-2 family and their protein partners | Q41099855 | ||
| Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials | Q41419107 | ||
| Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression. | Q41444248 | ||
| The proto-oncogene Bcl-2 and its role in regulating apoptosis | Q41492030 | ||
| Induction of WAF1/CIP1 by a p53-independent pathway | Q42796161 | ||
| Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia | Q42814556 | ||
| Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development. | Q44217799 | ||
| Cell cycle regulators and human hepatocarcinogenesis. | Q52532853 | ||
| Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia | Q68134815 | ||
| Immunomodulatory effects of ursodeoxycholic acid on immune responses | Q68225187 | ||
| Molecular aspects of membrane stabilization by ursodeoxycholate [see comment] | Q70457384 | ||
| Effect of three different dihydroxy bile acids on intestinal cholesterol absorption in normal volunteers | Q71354019 | ||
| Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells | Q72200609 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia | Q73420797 | ||
| Apoptosis and the expression of Bax and Bcl-2 in squamous cell carcinoma and adenocarcinoma of the uterine cervix | Q77387023 | ||
| Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group | Q77807948 | ||
| [p53 gene codon 72 polymorphism and genetic susceptibility to hepatocellular carcinoma in Chinese population] | Q81537020 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 1652-1658 | |
| P577 | publication date | 2007-03-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines | |
| P478 | volume | 13 |
| Q43092597 | Antibiotic treatment is superior to ursodeoxycholic acid on total parenteral nutrition associated hepatic dysfunction |
| Q39852728 | HA117 gene increased the multidrug resistance of K562 cells in vitro: an investigation to the function of a novel gene related to drug resistance |
| Q33414397 | Intrinsic anticarcinogenic effects of Piper sarmentosum ethanolic extract on a human hepatoma cell line |
| Q24630357 | MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network |
| Q42798654 | Transformation and apoptosis of NIH/3T3 cells treated with nickel-smelting fumes |
| Q38946483 | Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis |
| Q37919924 | Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. |
| Q36085576 | Ursodeoxycholic acid induces apoptosis in hepatocellular carcinoma xenografts in mice |
| Q53020814 | Ursodeoxycholic acid induces apoptosis of hepatocellular carcinoma cells in vitro. |
| Q43281464 | Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma |
Search more.